Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can reduce production time from several weeks to just one day and cut costs by nearly 70%, potentially making advanced cancer tr… For the full story, visit the source.
BusinessMaharashtra
Tata-backed MedTherapy claims CAR-T breakthrough with one-day production
Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can reduce production time from several weeks to just one day and cut costs by nearly 70%, potentially making advanced cancer tr…
By Rica Bhattacharyya· The Times of India· 4 months ago· 2 min read
This summary is sourced from The Times of India. Read the full article at:The Times of India